Hepacivirus Concept

subject area of

• 5-(Perylen-3-yl)Ethynyl-arabino-Uridine (aUY11), an Arabino-Based Rigid Amphipathic Fusion Inhibitor, Targets Virion Envelope Lipids To Inhibit Fusion of Influenza Virus, Hepatitis C Virus, and Other Enveloped Viruses  Academic Article
• A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders  Academic Article
• Antibodies against Hepatitis C in a Population of Swedish Haemophiliacs and Heterosexual Partners  Academic Article
• Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database  Academic Article
• Biological and clinicopathological features associated with hepatitis C virus type 5 infections  Academic Article
• Class A Scavenger Receptor–Mediated Double-Stranded RNA Internalization Is Independent of Innate Antiviral Signaling and Does Not Require Phosphatidylinositol 3-Kinase Activity  Academic Article
• Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin  Academic Article
• Co-Infection by Hepatitis C Virus in HIV-Infected Patients in Southern Brazil: Genotype Distribution and Clinical Correlates  Academic Article
• Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada  Academic Article
• Design of Novel Rho Kinase Inhibitors Using Energy Based Pharmacophore Modeling, Shape-Based Screening, in Silico Virtual Screening, and Biological Evaluation  Academic Article
• Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis  Academic Article
• Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran—a multicenter study  Academic Article
• Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6  Academic Article
• Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma  Academic Article
• Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aboriginals in Canadian HIV-Hepatitis C Co-Infected Individuals  Academic Article
• Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts  Academic Article
• Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study  Academic Article
• Hepatitis C Virus-infected, HCV-RNA-negative Patients with Bleeding Disorders - Relationship to Age, HIV and Treatment  Academic Article
• Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy  Academic Article
• Hepatitis C genotypes in Australian haemophilia patients  Academic Article
• Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants  Academic Article
• Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis  Academic Article
• IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling  Academic Article
• Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes  Academic Article
• Identification of numerous hepatitis C virus genotypes in Montreal, Canada  Academic Article
• Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV–HCV coinfection before and after antiretroviral therapy  Academic Article
• Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study  Academic Article
• Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon  Academic Article
• Marijuana Use in Hepatitis C Infection does not Affect Liver Biopsy Histology or Treatment Outcomes  Academic Article
• Network meta-analysis of direct-acting antivirals in combination with peginterferon–ribavirin for previously untreated patients with hepatitis C genotype 1 infection  Academic Article
• Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: Clinically relevant or a diagnostic problem?  Academic Article
• Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C  Academic Article
• Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada)  Academic Article
• Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learning  Academic Article
• Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study  Academic Article
• Prevalence of hepatitis C infection in Hong Kong  Academic Article
• Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients  Academic Article
• Proceedings of a consensus conference: Blood-borne HIV and hepatitis—Optimizing the donor selection process†  Academic Article
• Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies  Academic Article
• Recommendations for the identification of chronic hepatitis C virus (HCV) infection among persons born during 1945 through 1965  Academic Article
• Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.  Academic Article
• Replication of Subgenomic Hepatitis C Virus Replicons in Mouse Fibroblasts Is Facilitated by Deletion of Interferon Regulatory Factor 3 and Expression of Liver-Specific MicroRNA 122  Academic Article
• Risk of Cardiovascular Disease Associated with HCV and HBV Coinfection among Antiretroviral-Treated HIV-Infected Individuals  Academic Article
• Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry  Academic Article
• Sex-Specific Risk Factors and Health Disparity Among Hepatitis C Positive Patients Receiving Pharmacotherapy for Opioid Use Disorder: Findings From a Propensity Matched Analysis  Academic Article
• Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis  Academic Article
• Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis  Academic Article
• The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes  Academic Article
• The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach  Academic Article
• Transmission of HIV and HCV within Former Soviet Union Countries  Academic Article
• Transmission of hepatitis C with pasteurised factor VIII  Academic Article
• Treatment responses in Asians and Caucasians with chronic hepatitis C infection  Academic Article